广州合和医药

Guangzhou Hehe Pharmaceutical Technology is a clinical-stage biotechnology company based in Guangzhou, China, focused on the discovery and development of innovative therapies for chronic infectious diseases and metabolic disorders. The company's pipeline features small molecule candidates such as HH-003, a TLR7 agonist for chronic hepatitis B, and HH-006, an FXR agonist for NASH. Additionally, Hehe has developed HH-120, an inhaled ACE2-fusion protein designed to neutralize SARS-CoV-2 variants. The company leverages its expertise in medicinal chemistry and biologics to address significant unmet medical needs in the global healthcare market. Founded by industry veterans, Hehe Pharma aims to bridge the gap between basic research and clinical application.